DEVELOPMENT OF A NEW IMMUNOMODULATING DRUG TIMOFER

Results of the development of an immunomodulating drug timofer based on coordination compounds isoleucyl-tryptophan dipeptide with iron (II), including the study of coordinate isoleucyl-tryptophan dipeptide with iron (II), the study of the immunostimulatory activity of the coordination compounds, the results of the preclinical and clinical studies of timotsin are presented. Method of pH titration showed that the interaction of zinc and dipeptide isoleucyl-tryptophan formed in solution following complex forms: [Fe (HL ±)] 2+ (β = 1,00×10 34), [Fe (HL ±) 2] 2+ (β = 6,25×10 11), [Fe (HL ±)OH] + (β = 4,01×10 26), [Fe (L -)] + (β = 8,10×10 18), [Fe (L -) 2] + (β = 7,50×10 28), [Fe (L -)OH] + (β = 1,03×10 29). It was shown that the immunostimulatory activity of the coordination compounds is 2 times higher than that starting dipeptide. The substance sample and standard formulation of timofer were developed and standardized. The developed immunomodulatory drug timofer showed a high therapeutic efficacy in the treatment of iron deficiency anemia patients with inflammatory processes and traumatic injuries of the maxillofacial region, with chronic inflammatory diseases of the the genitals (CMV, HSV, chlamydia, chronic endometritis, chronic salpingoopharitis, ureaplasmosis) with chronic bronchitis, chronic obstructive bronchitis, bronchial asthma, pneumonia, chronic glomerulonephritis, and chronic renal failure complicated by anemia Bright, withrheumatic diseases, gynecological patients with anemia of moderate and severe degrees of severity, at surgical treatment of patients with suppurative lung disease, heart disease and chronic pericarditis operated with cardiopulmonary bypass. Timofer is registered in Tajikistan (registration number of medical drug №002866).

immunomodulatory drug, timofer, coordination compounds, isoleucyl-tryptophan, iron